No Detail Found!

Epigallocatechin gallate prevents peritoneal fibrosis by inhibiting epithelial-mesenchymal transition in human peritoneal mesothelial cells

Author(s)
Lin Zhang Department of Nephrology, Fourth Changsha Hospital,Changsha,P.R. China
Yan Huang Department of Emergency, Fourth Changsha Hospital, Institute of Emergency,Changsha,P.R. China
Ni Zeng Department of Nephrology, Fourth Changsha Hospital,Changsha,P.R. China
Cangsang Liu Department of Nephrology, Fourth Changsha Hospital,Changsha,P.R. China
Yafen Jiang Department of Nephrology, Fourth Changsha Hospital,Changsha,P.R. China
Xi Pu Department of Nephrology, Fourth Changsha Hospital,Changsha,P.R. China
Abstract
The current study set out to elucidate the function of epigallocatechin gallate (EGCG) against peritoneal fibrosis in peritoneal dialysis (PD) patients. Firstly, human peritoneal mesothelial cells (HPMCs) were pretreated with 0, 12.5, 25, 50 or 100µmol/L EGCG. Epithelial-mesenchymal transition (EMT) models were induced by advanced glycation end products (AGEs). Untreated-cells were regarded as the blank control group. Changes in proliferation and migration were analyzed by MTT assay and scratch test and levels of HPMC epithelial and interstitial molecular marker proteins were measured by Western blot assay and immunofluorescence, while trans-endothelial resistance was assessed using an epithelial transmembrane cell resistance meter. Inhibition rates of HPMCs, migration numbers and the levels of Snail, E-cadherin, CK and ZO-1 were all decreased, while the levels of a-SMA and FSP1 and transcellular resistance values were increased in treatment groups (P<0.05). With the increase of EGCG concentrations, HPMCs growth inhibition rates and migration numbers, the levels of a-SMA and FSP1 and TER values were decreased and the levels of Snail, E-cadherin, CK and ZO-1 were enhanced (P<0.05). Overall, the current study highlights that EGCG effectively inhibits the proliferation and migration of HPMCs, increases permeability, suppresses EMT and ultimately delays peritoneal fibrosis.
Publication Details
Page(s) 1767-1772
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: 6, Year: 2022

Request the full text from PASTIC

Keywords
End-stage renal disease, Epigallocatechin gallate, peritoneal fibrosis, ultrafiltration, epithelial-mesenchymal transition
0

Citations

0

Downloads

67

Views